Buscar | SocioMint

Atess Karahan agregó una foto Other
2026-07-29 08:37:06 -

Neurofibromatosis Market Share Analysis and Industry Insights
"According to the latest report published by Data Bridge Market Research, the Neurofibromatosis Market The global neurofibromatosis market size was valued at USD 14.60 billion in 2024 and is expected to reach USD 36.66 billion by 2032, at a CAGR of 12.20% during the forecast period Neurofibromatosis Market report contains most-detailed market segmentation, systematic analysis of...

0 Commentarios 0 Acciones 840 Views 0 Vista previa

Please log in to like, share and comment!
Surbhi Verma agregó una foto Health
2026-07-10 10:32:21 -

MEK Inhibitors Market: How Is Neurofibromatosis Type 1 Approval Creating a New Rare-Disease Revenue Stream?
MEK inhibitors targeting neurofibromatosis type 1-associated plexiform neurofibromas — the oral allosteric MEK1/2 inhibitors selumetinib (Koselugo, AstraZeneca) and mirdametinib (Gomekli, SpringWorks Therapeutics) approved for pediatric and adult NF1 patients with symptomatic, inoperable tumors — represent the fastest-growing indication segment in the MEK inhibitor market, with the...

0 Commentarios 0 Acciones 1K Views 0 Vista previa

Please log in to like, share and comment!
Priti Mrfr16 agregó una foto Health
2026-09-10 08:38:00 -

Neurofibromatosis Type 1 Market – Advancing Targeted Therapies for Genetic Tumor Disorders
Market Overview The neurofibromatosis type 1 market is evolving as pharmaceutical innovation delivers targeted therapeutic options for this genetic disorder characterized by nervous system tumor growth. Recent advances in MEK inhibitor therapies and growing diagnostic awareness are reshaping treatment approaches for patients affected by this condition, which previously had limited...

0 Commentarios 0 Acciones 132 Views 0 Vista previa

Please log in to like, share and comment!